



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventors: Terwilliger and Lamoureux

Appln. No.: 10/682,359

Confirm. No.: 6087

Filed: October 9, 2003

Title: SHIELDED TRANSPORT FOR  
MULTIPLE BRACHYTHERAPY IMPLANTS  
WITH INTEGRATED  
MEASURING AND CUTTING BOARD

PATENT APPLICATION

Art Unit: 3735


Examiner: Gilbert, Samuel G.

Atty. Docket No.: WORLD-01011US0

Customer No. 23910

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being deposited in the United States Postal Service with sufficient postage as first class mail in an envelope addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**, on the date shown below.

 (Signature)  
Mathew Otts  
Signature Date: 4/12/07

**TRANSMITTAL LETTER RE INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application. MPEP §609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

***Enclosed with this statement are the following:***

04/17/2007 CNEGA1 03000021 061325 10682359

31 FC:1006 180.00 DA

Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. §609.

As allowed under 37 C.F.R. § 1.98(a)(2)(ii), no copies of the U.S. patents and U.S. patent application publications are enclosed, unless required by the office.

If any of the cited/submitted documents is in a foreign language, a concise explanation of relevance is provided pursuant to 37 C.F.R. §1.98(a)(3)(i). For foreign language documents cited in a search report by a foreign patent office, the requirement for a concise explanation of relevance is satisfied by the submission herewith of an English language version of the search report. MPEP §609A(3). If a written English-language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in §1.56(c), a copy of the translation accompanies this statement, 37 C.F.R. §1.98(a)(3)(ii), and satisfies the requirement for a concise explanation of relevance, MPEP §609A(3).

***This statement should be considered because:***

**37 C.F.R. §1.97(c).** Although it may not qualify under subsection (b), this statement qualifies under 37 C.F.R. §1.97, subsection (c) because:

(1) It is being filed before the mailing date of a FINAL Office Action, a Notice of Allowance, or an action that otherwise closes prosecution in the subject application, whichever occurs first.  
-- AND (*check at least one of the following*) --

— (a) It is accompanied by a STATEMENT as set forth in 37 C.F.R. §1.97(e).  
-- OR --

(b) It is accompanied by the \$180 fee set forth in 37 C.F.R. §1.17(p).

**Fee Authorization.** The Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325.

Respectfully submitted,

FLIESLER MEYER LLP

Date: Apr. 12, 2007

By:

  
Jeffrey R. Kurin  
Reg. No. 41,132

Customer No. 23910  
FLIESLER MEYER LLP  
650 California Street, 14th Floor  
San Francisco, California 94108  
Telephone: (415) 362-3800



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <small>(Subsidiary of the U.S. Patent and Trademark Office)</small>		Attorney Docket Number <b>WORLD-01011US0</b>	Serial/Patent Number <b>10/682,359</b>
<i>Information Disclosure Statement</i> <b>BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		Applicant/Patent Owner <b>Terwilliger et al.</b>	
		Filing/Issue Date <b>Oct. 9, 2003</b>	Group Art Unit <b>3735</b>

### U.S. PATENTS

Examiner Initial		Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
		2,575,138	11/13/51	Slaughter			
		3,752,630	08/14/73	Takagi			
		3,811,426	05/21/74	Culver et al.			
		3,936,414	02/03/76	Wright et al.			
		4,416,308	11/22/83	Simpson et al.			
		4,702,228	10/27/87	Russell et al.			
		4,754,745	07/05/88	Horowitz			
		4,784,116	11/15/88	Russel Jr., et al.			
		4,891,165	01/02/90	Suthanthiran			
		4,936,823	06/26/90	Colvin et al.			
		4,946,435	08/07/90	Suthanthiran et al.			
		5,022,940	06/11/91	Mehoudar			
		5,242,373	09/07/93	Scott et al.			
		5,860,909	01/19/99	Mick et al.			
		6,099,457	08/08/00	Good, Roger			
		6,132,947	10/17/00	Honan et al.			
		6,216,932 B1	04/10/01	Schmidt			
		6,264,599 B1	07/24/01	Slater et al.			
		6,273,851 B1	08/14/01	Slater et al.			
		6,327,490 B1	12/04/01	Spetz			
		6,356,195 B1	03/19/02	Green et al.			

**U.S. PATENTS**

Examiner Initial		Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
		6,360,116 B1	03/19/02	Jackson, Jr. et al.			
		6,387,034 B1	05/14/02	Lee			
		6,398,709 B1	06/04/02	Ehr et al.			
		6,403,916 B1	06/11/02	Spooner et al.			
		6,428,504 B1	08/06/02	Riaziat et al.			
		6,438,401 B1	08/20/02	Cheng et al.			
		6,450,937 B1	09/17/02	Mercereau et al.			
		6,450,938 B1	09/17/02	Miller			
		6,474,535 B1	11/05/02	Shanks et al.			
		6,500,109 B2	12/31/02	Tokita et al.			
		6,549,802 B2	04/15/03	Thornton			
		6,561,967 B2	05/13/03	Schmidt			
		6,572,525 B1	06/03/03	Yoshizumi			
		6,572,527 B2	06/03/03	Steele, Sr. et al.			
		6,575,888 B2	06/10/03	Zamora et al.			
		6,595,908 B2	07/22/03	Loffler et al.			
		6,599,231 B1	07/29/03	Elliot et al.			
		6,616,593 B1	09/09/03	Elliot et al.			
		6,616,594 B2	09/09/03	Fontayne et al.			
		6,626,817 B2	09/30/03	Luth			
		6,632,176 B2	10/14/03	McIntire et al.			
		6,638,206 B2	10/28/03	Green et al.			
		6,656,106 B2	12/02/03	Schmidt			
		6,656,107	12/02/03	Pedersen et al.			
		6,682,471 B2	01/27/04	Stelle, St. et al.			
		6,669,622 B2	12/30/03	Reed et al.			

### U.S. PATENTS

Examiner Initial	Patent Number	Issue Date	First Named Inventor	Class	Subclass	Filing Date
	6,709,381 B2	03/23/04	Munro, III			
	6,746,661 B2	06/08/04	Kaplan			
	6,752,753 B1	06/22/04	Hoskins et al.			
	6,755,775 B2	06/29/04	Kalas et al.			
	6,761,680	07/13/04	Terwilliger et al.			
	6,786,858 B2	09/07/04	Terwilliger et al.			
	6,820,318 B2	11/23/04	Terwilliger et al.			
	6,837,844 B1	01/04/05	Ellard et al.			
	6,846,283	01/25/05	Green et al.			
	6,905,455	06/14/05	Rapach et al			
	6,911,000	06/28/05	Mick et al.			
	6,926,657 B1	08/09/05	Reed et al.			
	7,008,367 B2	03/07/06	Visscher et al.			

### U.S. PATENT PUBLICATIONS

Examiner Initial	Patent Application Publication Number	Publication Date	Applicant
	US2003/0084988 A1	05/08/03	Terwilliger et al.
	US2003/0092958 A1	05/15/03	Terwilliger et al.
	US2004/0158117 A1	08/12/04	Drobnik et al.
	US2004/0158118 A1	08/12/04	Drobnik et al.

### PENDING U.S. PATENT APPLICATIONS

Examiner Initial	Application Number	Filing Date	First Named Inventor	Petition to Expunge? Yes   No

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Abstract Yes   No
	EP 0 466 681 B1	01/15/92	Europe			X
	WO 00/64538	02/11/00	WIPO			
	WO 00/61229	10/19/00	WIPO			

**OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)**

	Medi-Physics brochure entitled "I-125 Seeds. No. 6711, Medi-Physics, Inc. Arlington Heights Il. 60004, USA; Revised. October 1999, 2 pages
	Medi-Physics brochure entitled "I-125 Seeds. No. 7000; Medi-Physics, Inc. Arlington Heights Il. 60004, USA; Revised. October 1999, 2 pages
	Amersham Health; "EchoSeed™"; <a href="http://www.amershamhealth-us.com/echoseed/">http://www.amershamhealth-us.com/echoseed/</a> printed 11/19/2003
	Amersham Health; "Rapid Strand Indications"; <a href="http://www.amershamhealth-us.com/products/index.htm?a=i&amp;i=38">http://www.amershamhealth-us.com/products/index.htm?a=i&amp;i=38</a> ; printed 11/19/2003
	Amersham Health; "OncoSeed Indications"; <a href="http://www.amershamhealth-us.com/oncoseed/">http://www.amershamhealth-us.com/oncoseed/</a> ; printed 11/19/2003
	RadioMed: Innovative Products for Radiation, "The Visicoil Advantage...for Image Guided Radiation Therapy," <a href="http://www.radiomed.com/visicoil/">http://www.radiomed.com/visicoil/</a> , at lease as early as August, 2003.
	Ocura, "RapidStrandRx: The Logical Choice for Improved Dosimetry," Ocura Inc., Plymouth Meeting, PA, April, 2005.

Examiner	Date Considered

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*1 = Copy not submitted because it was submitted in prior application SN / \_\_\_\_\_, filed \_\_\_\_\_, 20\_\_\_\_\_, relied on under 35 USC §120.

\*2 = Copy not submitted because it was submitted in prior application SN / \_\_\_\_\_, filed \_\_\_\_\_, 20\_\_\_\_\_, relied on under 35 USC §120.